The combined company will be the largest dedicated biologics contract research organisation in the US
LakePharma, a US contract research organisation (CRO) specialising in antibody and protein engineering, cell line development, and protein production, has acquired Blue Sky BioServices, a CRO offering protein and antibody production and assay services.
Financial details remain confidential.
The combined company will be known as LakePharma, and will be the largest dedicated biologics CRO in the US, providing a range of protein and antibody-related development services to the pharmaceutical and biotechnology markets.
Worcester, MA-based Blue Sky BioServices is a portfolio company of Ampersand Capital Partners and as part of the transaction, Ampersand has made an investment in LakePharma to support growth initiatives.
The combination brings together LakePharma's expertise in antibody development, protein expression and characterisation, molecular biology and process development with Blue Sky's leadership in bacterial and baculovirus systems, complementary molecular biology platforms, and assay services.
LakePharma employs nearly 100 people and has four facilities located in the key San Francisco Bay Area and Cambridge/Boston biotech hubs.